Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth

Request Free Sample Buy Report

Anti-Asthmatic And COPD Drugs Market 2021 - By Drug Class (Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs), By End User (Asthma Patients, COPD Patients), By Distribution Channel (General Pharmacies, Hospital Pharmacies, Online Retailers), By Therapy (Preventive, Curative), By Route Of Administration (Oral, Inhaled, Intravenous, Subcutaneous), By Age Group (Below 5, 5-14, 15-60, Above 60), By Prescription (Prescription, Over The Counter (OTC)), By Drug Type (Branded, Generic) And By Region, Opportunities And Strategies – Global Forecast To 2030

Starting Price : $5000.00 | Pages : 345 | Published : August 2021 | | Format : pdf

Purchase Options

Request Sample

Request For Discount

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

Anti-Asthmatic and COPD Drugs Definition

The anti-asthmatics and COPD drugs market consists of sales of anti-asthmatics and COPD drugs by entities (organizations, sole traders and partnerships) that manufacture anti-asthmatics and COPD drugs which are used to prevent and treat asthma and chronic obstructive pulmonary disease (COPD). The anti-asthmatics and COPD drug industry includes establishments that manufacture anti-asthmatics and COPD drugs such as bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs.

Asthma is a condition that causes the airways in the body to narrow and swell and generate extra mucus. This can make breathing difficult, resulting in coughing, wheezing on exhalation and shortness of breath. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction in the lungs. Breathing difficulties, cough, mucus production and wheezing are all symptoms.

Anti-Asthmatic and COPD Drugs Size

The global anti-asthmatics and COPD drugs market reached a value of nearly $75,376.4 million in 2020, having increased at a compound annual growth rate (CAGR) of 12.7% since 2015. The market is expected to grow from $75,376.4 million in 2020 to $86,436.2 million in 2025 at a rate of 2.8%. The anti-asthmatics and COPD drugs market is then expected to grow at a CAGR of 5.8% from 2025 and reach $114,413.5 million in 2030.

Growth factors in the historic period include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, and rise in healthcare expenditure. The market was restrained by expiration of patents, political uncertainties.

Going forward increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, increasing consumption of fats will drive the growth in the anti-asthmatics and COPD drugs market. Factors that could hinder the growth of the market in the future include side effects associated with respiratory drugs, reduction in free trade, stringent regulations.

Anti-Asthmatic and COPD Drugs Drivers

The key drivers of the anti-asthmatic and COPD drugs market include:

Increased Popularity Of E-Cigarettes/ Vaping

E-cigarette, a substitute of direct tobacco smoking is gaining popularity. E-cigarette smoking/ vaping incurs risk of developing asthma among individuals as it contains nicotine extracts from tobacco. E-cigarettes which are also known as e-cigs, vaporizer cigarettes, and vape pens are electronic battery-operated devices that emit doses of vaporized nicotine, or non-nicotine solutions to provide a similar sensation of inhaling tobacco to the user. The usage of e-cigs has been increasing. For instance, in the USA, as of 2020, 19.6% of high school students and 4.7% of middle school students were reported using an e-cigarette. The number of users of e-cigarettes is expected to increase further. Rising adoption of e-cigs will increase the number of asthma patients in the forecast period, which in turn is expected to drive the anti-asthmatics and COPD drugs market during this period.

Anti-Asthmatic and COPD Drugs Restraints

The key restraints on the anti-asthmatic and COPD market include:

Side Effects Associated With Respiratory Drugs

Side effects associated with respiratory drugs are expected to limit the growth of the market in the forecast period. Asthma and CPOD patients suffer from several side effects of respiratory drugs. The major side effects include dry mouth, headaches, constipation, fast heartbeat, muscle cramps and shaking. Inhaled steroids used for asthma treatment can sometime cause thrush (a yeast infection in the mouth) and hoarseness. Therefore, doctors are increasingly recommending alternate therapy such as herbs and dietary supplements, yoga, relaxation and acupuncture to their patients. An increasingly preference of alternative therapies for the treatment of asthma and COPD is expected to limit the growth of the anti-asthmatic and COPD drugs market in the forecast period.

Anti-Asthmatic and COPD Drugs Trends

The key trends influencing in anti-asthmatic and COPD drugs include:

Use Of Probiotics To Treat Asthma

Probiotics are gaining popularity in the market of anti-asthmatics and COPD drugs for the treatment of patients with asthma. Probiotics can enhance the host immune system through the gut ecosystem and could be beneficial for the treatment of allergic diseases such as asthma. For example, in November 2020, Activated Probiotics, an Australia based company manufacturing premium probiotic products, announced that they are expanding their range and developing probiotic products for the treatment of asthma.

Bioelectric Medicine For Asthma Patients

Companies in the anti-asthmatics and COPD drugs market are increasingly developing bioelectric medicines for the treatment of asthma patients. Bioelectronic Medicine focuses on electrical signaling in the nervous system to tackle a wide range of chronic diseases using miniaturized, implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses. In July 2020, electroCore, Inc., a US based bioelectronic medicine company, received FDA approval for nerve stimulator for asthma patients which were potentially affected by the novel coronavirus.

Opportunities And Recommendations In The Anti-Asthmatic and COPD Drugs

Opportunities –The top growth potential in the anti-asthmatics and COPD drugs market by drug class will arise in monoclonal antibodies market, which will gain $5,055.64 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by end user will arise in the asthma patients market, which will gain $6,249.5 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by distribution channel will arise in general pharmacies market, which will gain $4,863.6 million of global annual sales by 2025. The anti-asthmatics and COPD drugs market size will gain the most in the China’s anti-asthmatics and COPD drugs market at $4,273.5 million.

Recommendations-To take advantage of the opportunities, The Business Research Company recommends the anti-asthmatics and COPD drugs companies to focus on invest in probiotic drugs, focus on bioelectric medicines, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, premium pricing for branded drugs, companies should focus on increasing awareness on asthma and COPD, leveraging medical advice that asthmatics should ensure they consistently stay up to date with preventative medication to protect against COVID 19, target geriatric populations

Anti-Asthmatic and COPD Drugs Segmentation

The anti-asthmatic and COPD drugs market is segmented by drug class, end user, by distribution channel, by therapy, by route of administration, by age group, by prescription, by drug type and by geography.
By Drug Class –
The anti-asthmatic and COPD market is segmented by drug class into

a) Bronchodilators
b) Monoclonal Antibodies
c) Anti-inflammatory Drugs
d) Combination Drugs

The combination drugs market was the largest segment of the anti-asthmatics and COPD drugs market segmented by drug class, accounting for 37.4% of the total in 2020. Going forward, the monoclonal antibodies market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by drug class, at a CAGR of 6.3% during 2020-2025.
By End User –
The anti-asthmatic and COPD market is segmented by end user into

a) Asthma Patients
b) COPD Patients

The asthma patients end user market was the largest segment of the anti-asthmatics and COPD drugs market segmented by end user, accounting for 61.6% of the total in 2020. Going forward, the COPD patients end user market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by end user, at a CAGR of 3.1% during 2020-2025.
By Distribution Channel –
The anti-asthmatic and COPD market is segmented by distribution channel into

a) General Pharmacies
b) Hospital Pharmacies
c) Online Retailers

The general pharmacies distribution channel market was the largest segment of the anti-asthmatics and COPD drugs market segmented by distribution channel, accounting for 65.3% of the total in 2020. Going forward, the online retailers distribution channel market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by distribution channel, at a CAGR of 8.0% during 2020-2025.
By Therapy –
The anti-asthmatic and COPD market is segmented by therapy into

a) Preventive
b) Curative

The preventive was the largest segment of the anti-asthmatics and COPD drugs market by therapy, accounting for $40,897.4 million or 54.3% of the total market in 2020.
By Route of Administration –
The anti-asthmatic and COPD market is segmented by route of administration into

a) Oral
b) Inhaled
c) Intravenous
d) Subcutaneous

The anti-asthmatics and COPD drugs market is also segmented by route of administration into inhaled, intravenous and subcutaneous, and oral. The inhaled route of administration was the largest segment of the anti-asthmatics and COPD drugs market by route of administration, accounting for $55,104.4 million or 73.1% of the total market in 2020.
By Age Group –
The anti-asthmatic and COPD market is segmented by age group

a) Below 5
b) 5-14
c) 15-60
d) Above 60

The 15-69 Years age group was the largest segment of the anti-asthmatics and COPD drugs market by age group, accounting for $37,950.2 million or 50.3% of the total market in 2020.
By Prescription –
The anti-asthmatic and COPD market is segmented by prescription into

a) Prescription
b) Over The Counter (OTC)

The prescription was the largest segment of the anti-asthmatics and COPD drugs market by prescription, accounting for $70,421.1 million or 93.4% of the total market in 2020.
By Drug Type –
The anti-asthmatic and COPD market is segmented by drug type into

a) Branded
b) Generic

The branded was the largest segment of the anti-asthmatics and COPD drugs market by drug type, accounting for $72,029.6 million or 95.6% of the total market in 2019.
By Geography –
The anti-asthmatic and COPD market is segmented by geography into

• China
• India
• Japan
• Australia
• Indonesia
• South Korea

• USA

• Brazil

• France
• Germany
• UK

• Russia

North America was the largest region in the anti-asthmatics and COPD drugs market, accounting for 47.1% of the total in 2020. It was followed by the Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the anti-asthmatics and COPD drugs market will be Asia-Pacific and Middle East where growth will be at CAGRs of 6.6% and 4.1% respectively during 2020-2025. These will be followed by Africa and North America, where the markets are expected to register CAGRs of 2.9% and 1.8% respectively during 2020-2025.

Anti-Asthmatic and COPD Drugs Competitive Landscape

Major Competitors In The Anti-Asthmatic and COPD Drugs Market Are:

GlaxoSmithKline plc

AstraZeneca plc

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche Ltd.

Novartis AG

Other Competitors In The Anti-Asthmatic and COPD Drugs Market Include:

Sanofi S.A.

Chiesi Farmaceutici S.p.A.

Teva Pharmaceutical Industries Limited

Merck & Co., Inc.

Abbott Laboratories

Ache

Adcock Ingram

Apotex Inc

ASGEN Pharmaceutical Co., Ltd

Aspen Nigeria

Aurobindo Pharma Limited

Bayer

Biolab Farmaceuticad

Bristol Myers Squibb

China Meheco Group Co., Ltd

China National Pharmaceutical Group Co., ., Ltd. (Sinopharm)

Cipla Limited

Cristalia

Daewoong Pharmaceutical Co., Ltd

EMS Pharma

Eurofarma

Hanmi Pharmaceutical

Hypermarcas

Jiangsu Hengrui Medicine Co., Ltd

Julphar

KYORIN Holdings, Inc

Libbs

Lupin Limited

Mylan

Neopharma

Nichi-Iko Pharmaceutical Co., Ltd

Otsuka Pharmaceutical Co., Ltd.

Pfizer

Shanghai Acebright Pharmaceuticals Group Co., Ltd.

Shanghai Anovent Pharma

Vectura Group

Table Of Contents

Table 1: Global Anti-Asthmatics And COPD Drugs Market, Product Pipeline Analysis

Table 2: Global Anti-Asthmatics And COPD Drugs Market, Top 10 Drugs Sales, 2020

Table 3: Global Anti-Asthmatics And COPD Drugs Market, Patent Analysis Of Leading Drugs, 2020

Table 4: Anti-Asthmatics And COPD Drugs Market Regulatory Landscape

Table 5: Prevalence Of Asthma, 2015-2019

Table 6: Prevalence Of COPD, 2015-2019

Table 7: Global Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 8: Global Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 9: Global Anti-Asthmatics And COPD Drugs Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %

Table 10: Global Anti-Asthmatics And COPD Drugs Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 11: Global Anti-Asthmatics And COPD Drugs Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %

Table 12: Global Anti-Asthmatics And COPD Drugs Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 13: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 14: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 15: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 16: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 17: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 18: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 19: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Therapy, 2020

Table 20: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Route Of Administration, 2020

Table 21: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Patients’ Age Group, 2020

Table 22: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Type Of Prescription, 2020

Table 23: Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Type of Drug, 2020

Table 24: Asia Pacific GDP Per Capita, 2015-2020, $

Table 25: Asia Pacific, Population By Age Group, By Country, 2015-2023, Thousands

Table 26: Asia-Pacific Public Healthcare Expenditure, 2015-2019, $ Billion

Table 27: Asia-Pacific Private Healthcare Expenditure, 2015-2019, $ Billion

Table 28: Asia-Pacific Total Population Aged 65 And Above, 2015-2023, Thousands

Table 29: Air Pollution And Air Quality Index, Asia-Pacific Countries

Table 30: Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 31: Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 32: Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 33: Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 34: Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 35: Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 36: China GDP Per Capita, 2015-2020, $

Table 37: China, Population By Age Group, 2015-2023, Thousands

Table 38: China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2019, $ Billion

Table 39: China Total Population Aged 65 And Above, 2015-2023, Thousands

Table 40: China Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 41: China Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 42: China Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 43: China Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 44: China Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 45: China Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Millio

Table 46: India GDP Per Capita, 2015-2020, $

Table 47: India, Population By Age Group, 2015-2023, Thousands

Table 48: India Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2019, $ Billion

Table 49: India Total Population Aged 65 And Above, 2015-2023, Thousands

Table 50: India Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 51: India Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 52: India Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 53: India Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 54: India Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 55: India Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 56: Japan GDP Per Capita, 2015-2020, $

Table 57: Japan, Population By Age Group, 2015-2023, Thousands

Table 58: Japan Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2019, $ Billion

Table 59: Japan Total Population Aged 65 And Above, 2015-2023, Thousands

Table 60: Japan Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 61: Japan Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 62: Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 63: Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 64: Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 65: Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 66: Australia Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 67: Australia Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 68: Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 69: Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 70: Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 71: Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 72: Indonesia Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 73: Indonesia Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 74: Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 75: Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 76: Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 77: Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 78: South Korea Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 79: South Korea Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 80: South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 81: South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 82: South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 83: South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 84: Western Europe GDP Per Capita, 2015-2020, $

Table 85: Western Europe, Population By Age Group, By Country, 2015-2023, Thousands

Table 86: Western Europe Public Healthcare Expenditure, 2015-2019, $ Billion

Table 87: Western Europe Private Healthcare Expenditure, 2015-2019, $ Billion

Table 88: Western Europe Total Population Aged 65 And Above, 2015-2023, Thousands

Table 89: Air Pollution And Air Quality Index in 2018, Western Europe Countries

Table 90: Western Europe Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 91: Western Europe Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 92: Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 93: Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 94: Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 95: Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 96: UK GDP Per Capita, 2015-2020, $

Table 97: UK, Population By Age Group, 2015-2023, Thousands

Table 98: UK Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2019, $ Billion

Table 99: UK Total Population Aged 65 And Above, 2015-2023, Thousands

Table 100: UK Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 101: UK Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 102: UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 103: UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 104: UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 105: UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 106: Germany Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 107: Germany Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 108: Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 109: Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 110: Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 111: Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 112: France Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 113: France Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 114: France Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 115: France Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 116: France Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 117: France Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 118: Eastern Europe GDP Per Capita, 2015-2020, $

Table 119: Eastern Europe, Population By Age Group, By Country, 2015-2023, Thousands

Table 120: Eastern Europe Public Healthcare Expenditure, 2015-2019, $ Billion

Table 121: Eastern Europe Private Healthcare Expenditure, 2015-2019, $ Billion

Table 122: Eastern Europe Total Population Aged 65 And Above, 2015-2023, Thousands

Table 123: Eastern Europe Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 124: Eastern Europe Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 125: Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 126: Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 127: Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 128: Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 129: Russia Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 130: Russia Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 131: Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 132: Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 133: Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 134: Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 135: North America GDP Per Capita, 2015-2020, $

Table 136: North America, Population By Age Group, By Country, 2015-2023, Thousands

Table 137: North America Public Healthcare Expenditure, 2015-2019, $ Billion

Table 138: North America Private Healthcare Expenditure, 2013-2017, $ Billion

Table 139: North America Total Population Aged 65 And Above, 2015-2023, Thousands

Table 140: North America Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 141: North America Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 142: North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 143: North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 144: North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 145: North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 146: USA GDP Per Capita, 2015-2020, $

Table 147: USA, Population By Age Group, 2015-2023, Thousands

Table 148: USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2019, $ Billion

Table 149: USA Total Population Aged 65 And Above, 2015-2023, Thousands

Table 150: USA Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 151: USA Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 152: USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 153: USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 154: USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 155: USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 156: South America GDP Per Capita, 2015-2020, $

Table 157: South America, Population By Age Group, By Country, 2015-2023, Thousands

Table 158: South America Public Healthcare Expenditure, 2015-2019, $ Billion

Table 159: South America Private Healthcare Expenditure, 2015-2019, $ Billion

Table 160: South America Total Population Aged 65 And Above, 2015-2023, Thousands

Table 161: South America Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 162: South America Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 163: South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 164: South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 165: South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 166: South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 167: Brazil Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 168: Brazil Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 169: Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 170: Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 171: Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 172: Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users , Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 173: Middle East GDP Per Capita, 2015-2020, $

Table 174: Middle East, Population By Age Group, By Country, 2015-2023, Thousands

Table 175: Middle East Public Healthcare Expenditure, 2015-2019, $ Billion

Table 176: Middle East Private Healthcare Expenditure, 2015-2019, $ Billion

Table 177: Middle East Total Population Aged 65 And Above, 2015-2023, Thousands

Table 178: Middle East Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 179: Middle East Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 180: Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 181: Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 182: Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 183: Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 184: Africa GDP Per Capita, 2015-2020, $

Table 185: Africa, Population By Age Group, By Country, 2015-2023, Thousands

Table 186: Africa Public Healthcare Expenditure, 2015-2019, $ Billion

Table 187: Africa Private Healthcare Expenditure, 2015-2019, $ Billion

Table 188: Africa Total Population Aged 65 And Above, 2015-2023, Thousands

Table 189: Africa Anti-Asthmatics And COPD Drugs Market, Historic, 2015 – 2020, $ Million

Table 190: Africa Anti-Asthmatics And COPD Drugs Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 191: Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 192: Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 193: Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 194: Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 195: Global Anti-Asthmatics And COPD Drugs Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)

Table 196: GlaxoSmithKline – Financial Overview, 2016 - 2020, $ Billion

Table 197: AstraZeneca plc. – Financial Overview, 2016 - 2020, $ Billion

Table 198: Boehringer Ingelheim GmbH – Financial Overview, 2016 - 2020, $ Billion

Table 199: F. Hoffmann-La Roche Ltd – Financial Overview, 2016 - 2020, $ Billion

Table 200: Novartis AG – Financial Overview, 2016 - 2020, $ Billion

Table 201: Global Respiratory Diseases Drugs Market, Segmentation By Type, 2015 – 2025, $ Billion

Table 202: Global Respiratory Diseases Drugs Market, 2020, Split By Region

Table 203: Global Respiratory Diseases Drugs Market, 2015 – 2025, Historic And Forecast Growth Rate, Split By Region

Table 204: Global Anti-Asthmatics And COPD Drugs Market Size Gain ($ Million), 2020 – 2025, By Country

Table 205: Global Anti-Asthmatics And COPD Drugs Market Size Gain ($ Million), Segmentation By Drug Class, 2020 – 2025

Table 206: Global Anti-Asthmatics And COPD Drugs Market Size Gain ($ Million), Segmentation By End Users, 2020 – 2025

Table 207: Global Anti-Asthmatics And COPD Drugs Market Size Gain ($ Million), Segmentation By Distribution Channel, 2020 – 2025

Table 208: Anti-Asthmatics And COPD Drugs - Market Data Sources

List Of Tables